🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🐭❄️ Temperature impacts molecular changes linked to cancer & cachexia in mouse models -something to consider when interpreting preclinical results and their translation to human cancers. Huge thanks to Andrea Irazoki & team onlinelibrary.wiley.com/doi/10.1002/jc…

Statin use increases survival in #CLL. Wonder what other lipid lowering approaches would do 🤔 CLLSA ashpublications.org/bloodadvances/…

AICR's 10 Cancer Prevention Recommendations can also be followed after a cancer diagnosis. This helpful infographic outlines why nutrition and physical activity should be part of your cancer treatment program from day one: bit.ly/48zk3Mw

See our latest ARCHES analysis showing PSA nadir long term survival outcomes. ENZA/ADT durably beneficial even in those w/low PSA levels on initial ADT JAMA Network Open Arun Azad jamanetwork.com/journals/jaman… Duke Cancer DCI Center for Prostate & Urologic Cancers

After more than 100 cycles of chemotherapy, radiotherapy, and a life-saving stem cell transplant, Neil has been “given a second chance at life.” 💙 Read his journey: cureleukaemia.co.uk/community-blog…

We UBSportExR Uni of Birmingham are excited to be recruiting for an Assistant or Associate Professor in Exercise Physiology, deadline 5th June 2025 edzz.fa.em3.oraclecloud.com/hcmUI/Candidat…

If you have CLL, treatment decisions can be overwhelming. CLL Society’s Ambassador Program connects you with a patient who's had the treatment you're considering to answer questions & offer honest insights to help you feel more confident in your choices: bit.ly/43OSZK9

Every 14 mins someone in the UK is diagnosed with blood cancer. CLL is the most common of these blood cancers in adults. On #WorldBloodCancerDay let's honour those we have lost, support those living with blood cancer and raise awareness for better diagnosis and treatment options.

Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results:

Standing ovation at ⁦ASCO⁩ for the Challenge Trial. Take a look at this comparison of the magnitude of the exercise effect from Challenge versus multiple drug effects.

bbc.co.uk/news/articles/… Great to finally see this out, but Cancer Research UK nailed it for the UK-get it sorted Wes Streeting "This trial has the potential to transform clinical practice, but only if health services have the necessary funding and staff to make it a reality for patients"

Exercise has proven benefits for people with leukemia which is why being stuck at home due to the pandemic can be especially stressful even if its safer. Have you adapted with a home workout routine? Share in the discussion:myleukemiateam.com/resources/how-…

What an exciting few weeks for our team! We had a blast presenting our work and attending #ACSM in Georgia and #ASCO in Chicago. Huge kudos to Mary and Jocelyn for bringing our research to the scientific community!

A new Yale study shows for the first time that immune-system T cells are present in the brain, sent by the gut to a region that regulates hunger and thirst — a finding about T-cell physiology “that changes everything,” says one researcher: bit.ly/4mB9O1Q #Yale

Health Sciences Surrey David Bartlett, PhD Section of Oncology #TopicOfCancer #Research #Guildford #Charity

Often labeled a backup fuel, ketone bodies are actually metabolic multitaskers; regulating inflammation, gene expression & epigenetics. 🧬 A new AEHS study explores their role in exercise and recovery. 🔗bit.ly/3FwKBFp #AEHS #Ketones #ExerciseScience #MetabolicHealth

CLL13 longer follow up - huge study and great presentation. Though GIV is superior, I would not use as SOC since the duration of therapy is longer (range 12-36 months) than ven/obi which is still quite excellent (and always 1 yr). And yes MRD still matters! #EHA25 #EHA2025

Presented at #EHA2025: Among patients with chronic lymphocytic leukemia, undetectable MRD and progression-free survival were more common with ibrutinib–venetoclax than with ibrutinib alone or chemoimmunotherapy, with benefits sustained at 5 years. Full FLAIR phase 3 trial